CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis
Open accessThe DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index; 9 of the 17 sources its claims cite were checked for support.
Abstract
BACKGROUND: . METHODS: After conducting preclinical in vitro and in vivo studies, we evaluated the safety and pharmacodynamic effects of single escalating doses of NTLA-2001 in six patients with hereditary ATTR amyloidosis with polyneuropathy, three in each of the two initial dose groups (0.1 mg per kilogram and 0.3 mg per kilogram), within an ongoing phase 1 clinical study. RESULTS: after a single dose. Serial assessments of safety during the first 28 days after infusion in patients revealed few adverse events, and those that did occur were mild in grade. Dose-dependent pharmacodynamic effects were observed. At day 28, the mean reduction from baseline in serum TTR protein concentration was 52% (range, 47 to 56) in the group that received a dose of 0.1 mg per kilogram and was 87% (range, 80 to 96) in the group that received a dose of 0.3 mg per kilogram. CONCLUSIONS: . (Funded by Intellia Therapeutics and Regeneron Pharmaceuticals; ClinicalTrials.gov number, NCT04601051.).
Overview
CoChat Summary
TL;DR
In six patients with hereditary ATTR amyloidosis with polyneuropathy, single intravenous doses of NTLA-2001, a CRISPR-Cas9 lipid nanoparticle therapy, produced dose-dependent reductions in serum TTR protein at day 28 and only mild adverse events. This interim phase 1 study provides early clinical proof of concept for in vivo CRISPR-Cas9 gene editing.
Key findings
- At day 28, mean reduction from baseline in serum TTR protein concentration was 52% (range, 47 to 56) in the 0.1 mg/kg group and 87% (range, 80 to 96) in the 0.3 mg/kg group.
- Adverse events occurred in three of six patients and were all grade 1 (mild); no serious adverse events were observed. One patient had a grade 1 infusion-related reaction, and increased d-dimer levels in five of six patients returned to baseline by day 7.
- Preclinical studies showed durable TTR knockout after a single dose: in primary human hepatocytes, NTLA-2001 had EC50 0.05 to 0.15 nmol/L and EC90 0.17 to 0.67 nmol/L, with ≥93.7% TTR editing and ≥95% reduction in TTR protein production; in cynomolgus monkeys, a single dose of Cyn-LNP at 3 or 6 mg/kg produced maximum whole-liver gene editing of 73% and >94% reduction in serum TTR protein sustained over 12 months.
Methods
- Interim results from two initial dose groups of a two-part, global, phase 1, open-label, multicenter study: six patients with hereditary ATTR amyloidosis with polyneuropathy received a single intravenous dose of NTLA-2001 at 0.1 mg/kg or 0.3 mg/kg (three patients each) between November 2020 and April 2021.
- Key eligibility included age 18 to 80 years, polyneuropathy due to hATTR amyloidosis with or without cardiomyopathy, body weight 50 to 90 kg, and lack of access to approved ATTR treatments; prior TTR stabilizers were permitted after washout.
- Serum TTR protein was measured by validated enzyme-linked immunosorbent assay at baseline and weeks 1, 2, and 4; analyses were descriptive, comparing baseline with day 28 as mean percentage change and range. Preclinical work included primary human hepatocytes, transgenic mice, and cynomolgus monkeys.
Limitations
- The paper states that the study involves a very small number of patients with limited follow-up to date, and that continued serial measurements are planned to confirm durability. It also states that these are interim results from the first two dose groups in an ongoing dose-escalation study.
- Evident from the text: the clinical portion is open-label with no control group, uses descriptive analyses only, reports safety and pharmacodynamic effects through day 28, and does not report clinical outcomes such as disease progression, quality of life, or mortality.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
7 Valid · 1 Not valid · 5 Not checked · 56 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“TTR, which has a normal physiological role in vitamin A transport. 31”
What the sources say
- Supportedcites [31] 31. Müller ML, Butler J, Heidecker B. Emerging therapies in transthyretin amyloidosis - a new wave of hope after years of stagnancy? Eur J Heart Fail 2020; 22: 39-53. source
The Introduction states that TTR physiologically transports retinol-binding protein. The Therapeutic antisense oligonucleotides section links this function to vitamin A levels, supporting the paraphrase that TTR normally plays a role in vitamin A transport. (LLM, conf=0.94)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“but are limited by the requirement for long-term administration to maintain TTR knockdown.”
What the sources say
- Partly supportedcites [12] 12. Adams D, Gonzalez-Duarte A, O'Riordan WD, et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. N Engl J Med 2018; 379: 11-21. sourceExperimental — accuracy not yet measured
The Trial Design and Regimens section reports patisiran infusions every three weeks for 18 months, and Pharmacodynamics reports sustained TTR reduction during that period. The paper does not establish that long-term administration is required to maintain knockdown after treatment stops, or that this limitation applies to current ATTR treatments generally. (LLM, conf=0.82)
- Not checked — no full text of the sourcecites [13] 13. Adams D, Polydefkis M, GonzálezDuarte A, et al. Long-term safety and efficacy of patisiran for hereditary transthyretin-mediated amyloidosis with polyneuropathy: 12-month results of an openlabel extension study. Lancet Neurol 2021; 20: 49-59. source
- Partly supportedcites [14] 14. Solomon SD, Adams D, Kristen A, et al. Effects of patisiran, an RNA interference therapeutic, on cardiac parameters in patients with hereditary transthyretin-mediated amyloidosis. Circulation 2019; 139: 431-43. sourceExperimental — accuracy not yet measured
The Methods (Study Design and Treatment; page unavailable) report patisiran infusions every three weeks for 18 months, and the introductory passage describes its reduction of TTR protein. The paper does not establish that long-term administration is required to maintain TTR knockdown or characterize that requirement as a limitation of current ATTR treatments generally. (LLM, conf=0.82)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“More extensive TTR knockdown is associated with greater improvement in neuropathic end points in patients with hATTR polyneuropathy. 12”
What the sources say
- Partly supportedcites [12] 12. Adams D, Gonzalez-Duarte A, O'Riordan WD, et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. N Engl J Med 2018; 379: 11-21. sourceExperimental — accuracy not yet measured
The Primary End Point section reports a correlation between the degree of TTR reduction and change in mNIS+7, a composite neuropathy measure, at 18 months. The paper reports improvements in other end points, but our copy does not link the extent of knockdown to improvement across those end points. (LLM, conf=0.86)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“circulating TTR is produced almost entirely (>99%) within the liver, 2”
What the sources say
- Partly supportedcites [2] 2. Gertz MA, Benson MD, Dyck PJ, et al. Diagnosis, prognosis, and therapy of transthyretin amyloidosis. J Am Coll Cardiol 2015; 66: 2451-66. sourceExperimental — accuracy not yet measured
The section labeled “Diagnosis and Classification” says TTR is synthesized primarily in the liver, supporting the liver as its main source. It does not give the claimed >99% figure for circulating TTR. No page number is available in our copy. (LLM, conf=0.86)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Inotersen is associated with serious side effects, including glomerulonephritis and decreased platelet counts. 17”
What the sources say
- Supportedcites [17] 17. Gertz MA, Scheinberg M, Waddington-Cruz M, et al. Inotersen for the treatment of adults with polyneuropathy caused by hereditary transthyretin-medi- - ated amyloidosis. Expert Rev Clin Pharmacol 2019; 12: 701-11. source
The Safety and tolerability section (p. 9) reports decreased platelet counts and glomerulonephritis in patients receiving inotersen, including severe cases. The Regulatory affairs section (p. 9) states that the US approval carries a black box warning for increased risks of thrombocytopenia and glomerulonephritis. (LLM, conf=0.94)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
43 more claims · 1 with their cited sources checked
Create a free account to see all 69 claims and every source verdict.
- Probably not a substantial claim. 11
- It may state two separate claims as one. 15
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“which has already lead to investigational new drugs in clinical trials (NCT04601051)”
From Off-target effects in CRISPR/Cas9 gene editing (2023) · cites this paper as Gillmore et al., 2021
The cited source says what the claim attributes to it.
In the citing paper
“Ionizable lipid nanoparticles (LNPs) are a promising non-viral delivery platform for mRNA nanomedicines (13, 14) that have been used to deliver siRNA and CRISPR-based gene editing therapies to the liver in postnatal mouse, non-human primate, and clinical studies with encouraging results (15–18).”
From Ionizable Lipid Nanoparticles for Therapeutic Base Editing of Congenital Brain Disease (2023) · cites this paper as [17]
Citations
Cites
A Programmable Dual-RNA–Guided DNA Endonuclease in Adaptive Bacterial Immunity
Jinek, M., Chylinski, K., Fonfara, I., Hauer, M., Doudna, J. A., & Charpentier, E. (2012) · Science · doi:10.1126/science.1225829 · Cited by 17,116
Development and Applications of CRISPR-Cas9 for Genome Engineering
Hsu, P. D., Lander, E. S., & Zhang, F. (2014) · Cell · doi:10.1016/j.cell.2014.05.010 · Cited by 5,762
Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis
Adams, D., Gonzalez-Duarte, A., O’Riordan, W. D., Yang, C.-C., Ueda, M., Kristen, A. V., Tournev, I., Schmidt, H. H., Coelho, T., Berk, J. L., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1716153 · Cited by 3,047
Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy
Maurer, M. S., Schwartz, J. H., Gundapaneni, B., Elliott, P. M., Merlini, G., Waddington-Cruz, M., Kristen, A. V., Grogan, M., Witteles, R., Damy, T., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1805689 · Cited by 2,857
Bae, S., Park, J., & Kim, J.-S. (2014) · Bioinformatics · doi:10.1093/bioinformatics/btu048 · Cited by 2,339
GUIDE-seq enables genome-wide profiling of off-target cleavage by CRISPR-Cas nucleases
Tsai, S. Q., Zheng, Z., Nguyen, N. T., Liebers, M., Topkar, V. V., Thapar, V., Wyvekens, N., Khayter, C., Iafrate, A. J., Le, L. P., et al. (2015) · Nature Biotechnology · doi:10.1038/nbt.3117 · Cited by 2,268
Li, H., Yang, Y., Hong, W., Huang, M., Wu, M., & Zhao, X. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-019-0089-y · Cited by 1,715
The Onpattro story and the clinical translation of nanomedicines containing nucleic acid-based drugs
Akinc, A., Maier, M. A., Manoharan, M., Fitzgerald, K., Jayaraman, M., Barros, S., Ansell, S., Du, X., Hope, M. J., Madden, T. D., et al. (2019) · Nature Nanotechnology · doi:10.1038/s41565-019-0591-y · Cited by 1,636
Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis
Benson, M. D., Waddington-Cruz, M., Berk, J. L., Polydefkis, M., Dyck, P. J., Wang, A. K., Planté-Bordeneuve, V., Barroso, F. A., Merlini, G., Obici, L., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1716793 · Cited by 1,452
Self-citationCRISPR–Cas9 genome editing induces a p53-mediated DNA damage response
Haapaniemi, E., Botla, S., Persson, J., Schmierer, B., & Taipale, J. (2018) · Nature Medicine · doi:10.1038/s41591-018-0049-z · Cited by 1,264
Cited by
Items 1,401–1,500 of 1,725
Novel mouse reporter models for the detection of genome editing events in vivoPreprint
Snow, K. J., Saville, E., Heffner, C. S., Gaitan, Y., Duryea, J., Leidy-Davis, T., Bechtel, L. J., Hannigan, S., Low, B. E., Rossius, J., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.04.29.721708 · Cited by 1
Koblas, T., Bittenglová, K., Abaffy, P., Zacharovová, K., Girman, P., Valihrach, L., Kříž, J., & Saudek, F. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.08.21.746224 · Cited by 1
Heterogeneity in cell-cycle dynamics of synthetic mRNA-induced β-cell proliferationPreprint
Bittenglová, K., Zacharovová, K., Tichánek, F., Leontovyč, I., Girman, P., Kříž, J., Saudek, F., & Koblas, T. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.09.11.750925
“The IVT mRNA-based approach has previously been used for cell fate manipulation, gene expression regulation, and gene editing with high efficiency (Koblas et al , 2019; Leontovyc et al , 2017; Warren et al , 2010; Gillmore et al , 2021).”
The RNA World: The Best of Times, the Worst of Times
VandenDriessche, T. (2021) · Human Gene Therapy · doi:10.1089/hum.2021.29173.tvd
“14 Six patients were treated with escalating doses of CRISPR/Cas nanoparticles (designated as NTLA-2001) (NCT04601051), which lead to a significant dose-dependent decrease in serum TTR levels (52% in the low-dose cohort [0.1 mg/kg] and 87% in the high-dose cohort [0.3 mg/kg]).”
InfluentialWitteles, R. M., & Ky, B. (2021) · JACC CardioOncology · doi:10.1016/j.jaccao.2021.09.002
Dorbala, S., & Clerc, O. F. (2021) · JACC CardioOncology · doi:10.1016/j.jaccao.2021.09.006
“and CRISPR-Cas9 gene editing reduced transthyretin levels (1,3).”
BackgroundCRISPR Gene Editing Reduces Disease-Causing Protein in Hereditary Transthyretin Amyloidosis
Collins, T. R. (2021) · Neurology Today · doi:10.1097/01.nt.0000797976.28800.9d
Cellular models and therapeutic perspectives in hypertrophic cardiomyopathy
Yigit, G., & Wollnik, B. (2021) · Medizinische Genetik · doi:10.1515/medgen-2021-2094
“Importantly, 3D cardiac models provide powerful tools for possible clinical applications of genome editing technologies, including CRISPR/Cas9-based approaches, opening up new perspectives for precision medicine and in vivo somatic genome editing approaches in HCM, as recently shown for genetic cardiomyopathy-associat…”
Quoi de neuf en recherche 2021 ?
Nassar, D. (2021) · Annales de Dermatologie et de Vénéréologie - FMC · doi:10.1016/s2667-0623(21)01526-9
“ont traité 6 patients ayant une ATTR par injection intraveineuse de sgARN complémentaire du gène de la transthyrétine avec l’ARNm de l’endonucléase Cas9, enveloppés dans une nanoparticule lipidique à tropisme hépatique [1].”
BackgroundBuijsen, R. A. M., Lacroix, A., Ochaba, J., O’Reilly, D., Abdullahu, L., McConnell, E. M., & on Behalf of the OTS Board of Directors (2022) · Nucleic Acid Therapeutics · doi:10.1089/nat.2021.29004.ots
Disease Modifying Therapies for Transthyretin Amyloid Cardiomyopathy
Macedo, A. V. S., Fernandes, F., & Lópes, R. D. (2021) · ABC Heart Failure & Cardiomyopathy · doi:10.36660/abchf.20210034
Phenotype of a second Irish variant causing hereditary amyloidogenic transthyretin amyloidosis
Asad, M., Bermingham, N., McNamara, B., et al. (2022) · Journal of Neurology · doi:10.1007/s00415-022-11115-w
“Another patient with CTS and mild polyneuropathy received diflunisal which was well tolerated and is one of six patients who received NTLA-2001, a new CRISPRCas9–based in vivo gene-editing therapy as part of a clinical trial [9].”
BackgroundAnswering to social issues – Delivery of mRNA vaccines and therapeutics
Uchida, S. (2022) · Drug Delivery System · doi:10.2745/dds.37.25
La modificación del código genético
Montoliu, L. (2021) · Tarbiya: Revista de investigación e innovación educativa · doi:10.15366/tarbiya2021.49.004
Solomon, M., Foderà, V., Langkilde, A. E., Elliot, P. M., Tagliavini, F., Forsyth, V. T., Klementieva, O. L., & Bellotti, V. (2022) · Journal of Translational Medicine · doi:10.1186/s12967-022-03420-9
“A second very promising and innovative approach uses the silencing of the expression of pathogenic protein through the deployment of oligonucleotide technology [4] or, as recently reported for the first time directly in patients, through the use of CRISPR-CAS9 gene silencing technology [5].”
BackgroundCelebrating a Decade of CRISPR-Fueled Genome Editing
Barrangou, R. (2022) · The CRISPR Journal · doi:10.1089/crispr.2022.29150.rba
Francis Collins Preaches Scalability in Efforts to Treat Rare Diseases
Davies, K. (2022) · GEN Biotechnology · doi:10.1089/genbio.2022.29032.kda
Can Cas13 Conquer Coronavirus?
Grinstein, J. D. (2022) · GEN Biotechnology · doi:10.1089/genbio.2022.29031.jgr
Inhibition of Subchondral PDGFR-β Ameliorates Aging-Related Osteoarthritis Through PAK1/NICD AxisPreprint
Wu, H., Xiao, Y., Lin, R., Lin, H., Chen, K., Lin, Y., Chai, Y., Li, C., Yu, B., & Cui, Z. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.4123503
Diagnostics and Prevention: Landscape for Technology Innovation in Precision Cardiovascular Medicine
Mauch, J., Thachil, V., & Tang, W. H. W. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-816861-5.00004-6
New frontiers in CRISPR/Cas9 delivery systems delivery for gene editingPreprint
Khoshaman, K., Nasiri, M., Rezaee, M., Izadi, F., Mehrara, A., Sadeghi, L., Rezaeian, Y., Rezaei, E., Zarei, E., Rahmanian, S., et al. (2022) · doi:10.22541/au.165493454.42208986/v1
Highly precise genome editing using enhanced CRISPR-Cas12a nickase modulePreprint
Kim, C. H., Kim, H., Lee, Y., Lee, H., Lim, K., Park, S. J., Huh, J., Kim, Y., Lee, D., Kim, K. M., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.08.27.505535 · Cited by 1
Enhanced Effector Activity of Mediator Kinase Module Deficient CAR-T CellsPreprint
Freitas, K. A., Belk, J. A., Sotillo, E., Dániel, B., Sandor, K. D., Klysz, D. D., Duong, V. T., Burdsall, K. A., Xu, P., Malipatlolla, M. B., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.09.02.506235
The road towards precision therapy for genetic epilepsies
Stevelink, R. (2022) · Utrecht University Repository (Utrecht University) · doi:10.33540/1102
Medicine of the future: a look through the keyhole
Tendera, M. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehac523 · Cited by 1
Patterning-mediated supramolecular assembly of lipids into nanopalms
Alsudir, S. A., Alharbi, A., Almalik, A., et al. (2022) · iScience · doi:10.1016/j.isci.2022.105344
“…stable lipid structures, which are increasingly adapted for a variety of medical products ranging from organs’ self-targeting for accelerating clinical trials (Alsudir et al., 2021), to mRNA delivery (Pfizer, 2012; Moderna, 2021), and CRISPER-Cas9 in-vivo gene editing (Gillmore et al., 2021).”
Preimplantation genetic testing for familial amyloid polyneuropathy
Sousa, M. (2022) · Reproductive Health · doi:10.1186/s12978-022-01491-x · Cited by 1
Selección de lo mejor del año 2022 en cardiopatías familiares y genética cardiovascular
Jiménez‐Jáimez, J., Villacorta, E., Zorio, E., Ripoll‐Vera, T., Ruiz, R. M., Bermúdez-Jiménez, F. J., & Freire, J. L. (2022) · REC CardioClinics · doi:10.1016/j.rccl.2022.11.001
Gene and Cell Therapy: How to Build a BioDrug
Baumeister, S. H. C., & Woolfrey, A. E. (2022) · Pediatric oncology · doi:10.1007/978-3-031-06357-2_6
Khunger, A., Chauhan, A., Kaushik, A. K., & Chaudhary, G. R. (2023) · Elsevier eBooks · doi:10.1016/b978-0-12-821240-0.00010-x
Gene Nanovector for Genome Therapy
Ma, D., & Xi, Z. (2022) · Springer eBooks · doi:10.1007/978-981-16-1313-5_60-1 · Cited by 1
Gasser, T. (2023) · Fortschritte der Neurologie · Psychiatrie · doi:10.1055/a-2002-5176
“In einer klinischen Studie wurde dieses Prinzip zur Behand-lung der Transthyretin Amyloidose angewandt [6].”
BackgroundAssaf, B. T., Harper, C. G., & Phillips, J. A. (2023) · Elsevier eBooks · doi:10.1016/b978-0-12-821047-5.00034-8 · Cited by 2
Self-citationNeuropathie amyloïde à transthyrétine : du diagnostic au traitement
Adams, D. (2023) · Bulletin de l Académie Nationale de Médecine · doi:10.1016/j.banm.2023.03.003
Kardiale Amyloidose: Aktuelle und zukünftige Therapieoptionen
Knoll, K., Fuchs, P., & Trenkwalder, T. (2023) · CardioVasc · doi:10.1007/s15027-023-2968-y
Treatment Updates for Neuropathy in Hereditary Transthyretin Amyloidosis
King, D., Lau, K. H. V., & Kaku, M. C. (2023) · Current Treatment Options in Neurology · doi:10.1007/s11940-023-00754-7 · Cited by 1
Introduction: regulation of biotechnology, between anxieties and trust in scientific progress
Herdegen, M. (2023) · Edward Elgar Publishing eBooks · doi:10.4337/9781035302055.00007
A Review on Gene Therapy for Cancer
Sose, M. A. S., & Bhosale, M. (2023) · International Journal of Research Publication and Reviews · doi:10.55248/gengpi.4.423.36713
Advancements in the Treatment of Transthyretin Amyloidosis
Wang, R., & Park, C. (2023) · Journal of Student Research · doi:10.47611/jsrhs.v12i1.3883
Gene Therapy and Therapeutic Genome Editing in Liver for Lipid Disorders
Rader, D. J. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-88286-6.00030-3
Autosomal and X-Linked Degenerative Ataxias: From Genetics to Promising Therapeutics
Hadji, A., Louit, A., Roy, V., Blais, M., Berthod, F., Gros‐Louis, F., & Dupré, N. (2023) · Contemporary clinical neuroscience · doi:10.1007/978-3-031-24345-5_5 · Cited by 1
CRISPR/Cas patents and health-related publications in South America
Frâncio, L., de Freitas, M. V., & Matte, Ú. D. S. (2023) · Anais da Academia Brasileira de Ciências · doi:10.1590/0001-3765202320220629 · Cited by 1
Genotype-Phenotype Correlation in Noonan Syndrome – Focus on LZTR1 and its Substrates
Busley, A. V. (2023) · eDiss (Georg-August-Universität Göttingen) · doi:10.53846/goediss-9890
Delivery systems and therapeutic applications of mRNA targeting the central nervous system
Uchida, S. (2023) · Drug Delivery System · doi:10.2745/dds.38.125
LANDEIRA, J. M., Fatira, E., Banno, K., & Tanaka, Y. (2023) · Scientia Marina · doi:10.3989/scimar.05327.066
Structure and engineering of miniature Acidibacillus sulfuroxidans Cas12f1Preprint
Wu, Z., Liu, D., Pan, D., Yu, H., Shi, J. F., Ma, J., Fu, W., Wang, Z., Zheng, Z., Qu, Y., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.07.03.547593
CRISPR-Cas9: A new approach to genome editing and clinical treatment
Meša, I. (2020) · Bioengineering Studies · doi:10.37868/bes.v3i1.id215
Advances in the Diagnosis and Treatment of Cardiac Amyloidosis
Simões, M. V., de Ávila, D. X., Garibaldi, P. M. M., et al. (2023) · ABC Heart Failure & Cardiomyopathy · doi:10.36660/abchf.20230024
“9 This revolutionary therapy would allow, in theory, permanent silencing of variant TTR protein expression with a single application.”
BackgroundA viable alternative for editor delivery
Eweje, F., & Bauer, D. E. (2023) · Blood · doi:10.1182/blood.2023021309
Walther, J., Porenta, D., Wilbie, D., Seinen, C. W., Benne, N., Yang, Q., de Jong, O. G., Lei, Z., & Mastrobattista, E. (2023) · SSRN Electronic Journal · doi:10.2139/ssrn.4580331
Chen, Y., Jiang, N., Ling, S., Liu, J., Lin, Y., Zhou, R., Yao, Z., Guo, X., & Xia, X. (2023) · SSRN Electronic Journal · doi:10.2139/ssrn.4593804
A Comprehensive Review on Chemistry and Biology of Tafamidis in Transthyretin Amyloidosis
Patil, M. B., Ghode, P., & Joshi, P. (2023) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/0113895575241556231003055323
Smart nanosystems for wound healing and infection control
Sabit, H., Abdel-Hakeem, M. A., Abdel-Ghany, S. E., & Montēt, D. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-95376-4.00010-1 · Cited by 1
Experiments and Clinical Trials Carried Out in Other Therapeutic Fields
Lemonnier, J., & Lemonnier, N. (2023) · Springer eBooks · doi:10.1007/978-3-031-39300-6_14
Systemic Diseases and the Heart
(2023) · American Registry of PathologyArlington, Virginia eBooks · doi:10.55418/9781933477299-ch21
Unleashing the potential of catalytic RNAs to combat mis-spliced transcripts
Khalifah, B. A., AlGhamdi, S. A., & Alhasan, A. H. (2023) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2023.1244377
Lipid Nanoparticle-Mediated Delivery of CRISPR-Cas9 for Therapeutic Gene Correction
Walther, J. (2023) · Utrecht University Repository (Utrecht University) · doi:10.33540/2032
Applications of CRISPR/Cas 9 Based Technologies in the Field of Pharmacology: A Traditional Review
Ustaömer, S., & Yaşar, Y. K. (2023) · Journal of Literature Pharmacy Sciences · doi:10.5336/pharmsci.2023-96500 · Cited by 1
Unraveling Exogenous DNA Processing in Cas4‐Lacking Crispr Systems: A Novel Bypass Pathway Explored
Su, X., Jin, X., Wang, Z., & Duan, S. (2023) · Advanced Biology · doi:10.1002/adbi.202300454
Cyclodextrin-based supramolecular carriers for biopharmaceuticals
Higashi, T. (2023) · Drug Delivery System · doi:10.2745/dds.38.277
Research Status in Transthyretin Amyloid Cardiomyopathy
李, 帅. (2024) · Advances in Clinical Medicine · doi:10.12677/acm.2024.141068
Advanced Therapy Medicinal Products: Clinical, Non-clinical, and Quality Considerations
Mastrobattista, E., Doevendans, E., van Til, N. P., Kemp, V., de Vrij, J., & Hoogendoorn, K. H. (2024) · Springer eBooks · doi:10.1007/978-3-031-30023-3_14 · Cited by 1
Gene-edited primary muscle stem cells rescue dysferlin-deficient muscular dystrophyPreprint
Escobar, H., Francescantonio, S. D., Marg, A., Zhogov, A., Krishna, S., Metzler, E., Petkova, M. V., Daumke, O., Kühn, R., & Spuler, S. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.02.12.579813
“52,53 Targeting muscle systemically with non-viral vectors is still a challenge, but recent efforts to deliver Cas9 mRNA using lipid-nanoparticle carriers have shown promising results in DMD mice and further developments are guaranteed.”
BackgroundGENOME EDITING: CLUSTERED REGULARLY INTERSPACED SHORT PALINDROMIC REPEAT (CRISPR/CAS9)
Клименко, І. С., & Haladza, M. V. (2023) · Modern medicine pharmacy and psychological health · doi:10.32689/2663-0672-2023-3-2
Molecular Genetic Therapies in the Muscular Dystrophies
Nicolau, S., & Flanigan, K. M. (2023) · Current clinical neurology · doi:10.1007/978-3-031-44009-0_18
Tang, K., Zhou, X., Fang, S., Vandenbulcke, E., Du, A., Shen, J., Cao, H., Zhou, J., Chen, K., Shan, X., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.03.14.585126
Yang, L., Chen, L., Yang, Z., Deng, L., Bai, R., Zhang, T., Wang, Z., & Li, S. (2024) · Genomics · doi:10.1016/j.ygeno.2024.110836
Cardiac Amyloidosis: Open Issues and Future Perspectives
Emdin, M., Vergaro, G., Aimo, A., Fontana, M., & Merlini, G. (2024) · Springer eBooks · doi:10.1007/978-3-031-51757-0_24
Self-citationPlasma Transthyretin and Its Ligands
Franzini, M., Sanguinetti, C., Musetti, V., Castiglione, V., Aimo, A., Vergaro, G., & Emdin, M. (2024) · Springer eBooks · doi:10.1007/978-3-031-51757-0_12
Yanoff, M., & Sassani, J. W. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-87822-7.00012-2
(2024) · Frontiers research topics · doi:10.3389/978-2-8325-4801-1
Repair of leukemia-associated single nucleotide variants via interallelic gene conversionPreprint
Silver, A. J., Brown, D. J., Olmstead, S. D., Watke, J., Gorska, A. E., Tanner, L., Ramsey, H. E., & Savona, M. R. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.04.16.587991
Bendelman, G., Carretero, M., de Arenaza, D. P., et al. (2024) · Revista del Hospital Italiano de Buenos Aires · doi:10.51987/revhospitalbaires.v44i1.353
“…tratamiento de soporte se recomienda la anticoagulación temprana en pacientes fibrilados, y diuréticos (preferiblemente diuréticos de asa como la furosemida en combinación con ahorradores de potasio, de ser necesario, para evitar una hipopota-semia que repercuta sobre el riesgo arritmogénico) 6 .”
BackgroundKardiomyopathie-Phänotypen – Unterschiede und Gemeinsamkeiten in der Behandlung
Bittner, D., & Raake, P. W. J. (2024) · Aktuelle Kardiologie · doi:10.1055/a-2285-8006
Application of CRISPR–Cas Technology in Drug Development
Altaf, S., Saleem, F., Ikram, H. M., Iftikhar, A., & Anwar, H. (2024) · Springer eBooks · doi:10.1007/978-981-97-0814-7_8 · Cited by 4
Principles of novel cellular and molecular cardiovascular therapeutics
Furtado, M., Ribeiro, M., Martins, S., Carvalho, T., & Carmo‐Fonseca, M. (2024) · Elsevier eBooks · doi:10.1016/b978-0-12-822951-4.00042-4
Takács, K., Varga, B., Farkas, V., Perczel, A., & Grolmusz, V. I. (2024) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2024.108863 · Cited by 1
“Recently, the amyloids gained increased attention as possible antiviral agents [6], or in one of the first successes in the human in vivo CRISPR-Cas9-based gene editing therapy of the transthyretin amyloidosis [7].”
BackgroundHerrador, L., Yun, S., & González‐Costello, J. (2024) · Medicina Clínica (English Edition) · doi:10.1016/j.medcle.2024.03.007
Gaedeke, J. (2024) · Nephrologie aktuell · doi:10.1055/a-2276-1494
Molecular Genetics of Primary Open-Angle Glaucoma
Aboobakar, I. F., Wiggs, J. L., & Segrè, A. V. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-13820-1.00144-4
Base editing of the GLB1 gene is therapeutic in GM1 gangliosidosis patient-derived cells
Rha, A. K., Kan, S., Andrade-Heckman, P., Christensen, C. L., Harb, J. F., & Wang, R. (2024) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2024.108568 · Cited by 1
2. Recent Progress in Neuropathy Therapy-Focusing on Nucleic Acid Medicine-
Sekijima, Y. (2023) · Nihon Naika Gakkai Zasshi · doi:10.2169/naika.112.1654
Further therapeutic applications of mRNA and saRNA
Hillery, A. M. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-28934-7.00007-8 · Cited by 1
Cardiogenetics: que será, será. Ou non?
Vlachopoulos, C. V., & Lazaros, G. A. (2024) · Hellenic Journal of Cardiology · doi:10.1016/j.hjc.2024.09.003
CRISPR/Cas9-based genetic engineering for translational research in neurological disorders
Megagiannis, P., Rouleau, G. A., & Zhou, Y. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-19041-4.00021-2
Genetics of the Cardiomyopathies: A Review for the Cardiologist
Scolari, F. L., Garbin, H. I., Beuren, T. M. A., Matheus, F. C., Mourilhe‐Rocha, R., & Bittencourt, M. I. (2024) · ABC Heart Failure & Cardiomyopathy · doi:10.36660/abchf.20240047 · Cited by 3
Preclinical development of viral vector gene therapies
Newman, M. S., Hudry, E., Brassard, J. A., & Cunningham, J. J. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-13344-2.00003-1
Schneller, J. L., Du, W., & Ding, H. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.12.030
(2000) · Time to knit · doi:10.1016/s0246-0378(24)76452-5
Neuropatie amiloidi ereditarie
Planté‐Bordeneuve, V., & Gendre, T. (2025) · EMC - Neurologia · doi:10.1016/s1634-7072(24)50005-8
10.1016/b978-3-437-21073-0.00047-7
(2000) · Time to knit · doi:10.1016/b978-3-437-21073-0.00047-7
10.1016/b978-3-437-21073-0.00034-9
(2000) · Time to knit · doi:10.1016/b978-3-437-21073-0.00034-9
CRISPR: fundamental principles and implications for anaesthesia
Perez, A. R., Mavrothalassitis, O., Chen, J. S., Hellman, J., & Gropper, M. A. (2025) · British Journal of Anaesthesia · doi:10.1016/j.bja.2024.11.040 · Cited by 1
Rosa, S. A., Ferreira, C., Conceição, I. M., Coelho, T., Marques, N. S., & Azevedo, O. M. (2025) · Revista Portuguesa de Cardiologia · doi:10.1016/j.repc.2024.11.008
Protective antigen-mediated delivery of an anti-CRISPR protein for precision genome editingPreprint
Vera, A. O., Truex, N. L., Sreekanth, V., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.02.23.639680
Liu, Y., Li, X., Xin, A., Zhang, Y., & Zhang, J. (2025) · International Journal of Medical Sciences · doi:10.7150/ijms.101888
“A TTR-modifier agent aims to knock down TTR genes using CRISPR-Cas9 and is underway (NCT04601051) [41].”
CRISPR/Cas9 gene editing for treating gene and protein disorders
Umeyor, C. E., Negi, P., Agarwal, R., Hanjankar, S. N., & Patravale, V. B. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-27416-9.00004-6
Saxena, S., Kabra, M., Abdeen, A. A., Tabima, D. M., Sinha, D., Rawding, P. A., Zhu, M., Xie, R., Kulkarni, T., Hanstad, G. M., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-76350-5 · Cited by 2
Macular Corneal Dystrophy: Past, Present, and Future
Baruah, A., Borborah, S., & Ponnam, S. P. G. (2025) · IntechOpen eBooks · doi:10.5772/intechopen.1009902
Unlocking the Genetic Tool Kit: The Future of Medicine with Gene Therapy
Sarkar, B. (2024) · Springer eBooks · doi:10.1007/978-3-031-38971-9_254-1
Metadata
- Authors
- Gillmore, J. D., Gane, E., Taubel, J., Kao, J., Fontana, M., Maitland, M. L., Seitzer, J., O’Connell, D., Walsh, K. R., Wood, K., Phillips, J., Xu, Y., Amaral, A., Boyd, A. P., Cehelsky, J. E., McKee, M. D., Schiermeier, A., Harari, O., Murphy, A., Kyratsous, C. A., Zambrowicz, B., Soltys, R., Gutstein, D. E., Leonard, J., Sepp-Lorenzino, L., & Lebwohl, D.
- Affiliations
- University of Auckland (NZ)
- From the National Amyloidosis Centre, Division of Medicine, University College London, Royal Free Hospital (J.D.G., M.F.) and Richmond Pharmacology, St. George’s University of London (J.T.) — both in London; New Zealand Clinical Research (E.G.), University of Auckland (E.G.), and the Department of Neurology, Auckland City Hospital (J.K.) — all in Auckland, New Zealand; Intellia Therapeutics, Cambridge, MA (M.L.M., J.S., D.O., K.R.W., K.W., J.P., Y.X., A.A., A.P.B., J.E.C., M.D.M., A.S., J.L., L.S.-L., D.L.); and Regeneron Pharmaceuticals, Tarrytown, NY (O.H., A.M., C.A.K., B.Z., R.S., D.E.G.).
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2021-08-05
- Volume
- 385
- Issue
- 6
- Pages
- 493-502
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W3177445623
- Cited by
- 1,801
- References
- 35
- Citations by year
- 2026: 349 · 2025: 332 · 2024: 368 · 2023: 336 · 2022: 328 · 2021: 84
- FWCI
- 228.71
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Funders
- Regeneron Pharmaceuticals
- Intellia Therapeutics
- Topics
- Health Sciences › Medicine › Internal Medicine › Amyloidosis: Diagnosis, Treatment, Outcomes
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › CRISPR and Genetic Engineering
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Keywords
- transthyretin amyloidosis, hereditary ATTR amyloidosis, CRISPR/Cas9 genome editing, in vivo gene therapy, prealbumin, polyneuropathy, single ascending dose, pharmacodynamics, safety
- MeSH terms
- Gene Editing, RNA, Guide, CRISPR-Cas Systems, Female, Humans, Infusions, Intravenous, Liposomes, Male, Middle Aged, Prealbumin, RNA, Messenger, RNA, Guide, Kinetoplastida, Gene Transfer Techniques, Amyloid Neuropathies, Familial, Nanoparticles, CRISPR-Cas Systems
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-09-27, under version 3 of the claim definition (prompt extract-v3).
A second model labelled each claim on 2026-09-27 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.



